Study guide
4.2 Medical & Medication History: Drug–Nutrient Interactions and Supplements
Board Certified Specialist in Renal Nutrition CSR
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Overview & Kidney Disease Foundations
1.1 CDR CSR Exam Structure, Eligibility, Logistics & the 2023 Content Outline 1.2 Renal Anatomy, Physiology & Glomerular Hemodynamics 1.3 CKD Etiology, KDIGO Staging & Progression Risk
2 Chapter 2: Domain 1 — Anthropometric & Body Composition Assessment
2.1 Dry Weight Determination, Fluid Assessment & Interdialytic Weight Gain 2.2 Anthropometric Measurement Standards (Knee Height, Skinfolds, Frame Size) 2.3 Body Composition Analysis: BIA, BIS, DXA & Handgrip Dynamometry
3 Chapter 3: Domain 1 — Nutrition-Focused Physical Findings & PEW Assessment Tools
3.1 Protein-Energy Wasting (PEW) Diagnostic Criteria & Pathophysiology 3.2 Subjective Global Assessment (7-Point SGA) in Dialysis 3.3 Malnutrition Inflammation Score (MIS) & Scoring Protocols 3.4 Nutrition-Focused Physical Exam (NFPE) for Muscle & Fat Loss
4 Chapter 4: Domain 1 — Diet, Medical, Medication & Psychosocial History
4.1 Dietary Intake Assessment & Food Frequency Methods in CKD 4.2 Medical & Medication History: Drug–Nutrient Interactions and Supplements 4.3 Psychosocial, Social & Functional History in Renal Nutrition Assessment
5 Chapter 5: Domain 1 — Medical Tests & Procedures by Treatment Modality
5.1 Hemodialysis Clinical Assessment & Vascular Access Considerations 5.2 Peritoneal Dialysis & Peritoneal Glucose Absorption Assessment 5.3 AKI, CRRT & Pediatric Renal Disease Assessment
6 Chapter 6: Domain 1 — Nutrition Diagnosis: Terminology, Etiology & Reasoning
6.1 Standardized Nutrition Diagnostic Terminology (NCP) in Nephrology 6.2 Etiology & Root-Cause Analysis for Renal Nutrition Problems 6.3 Diagnostic Reasoning for Fluid, Mineral & Protein Imbalances
7 Chapter 7: Domain 1 — Nutrition Diagnosis in Complex Patients
7.1 Formulating Valid PES Statements in Complex Dialysis Patients 7.2 Differentiating PEW, Sarcopenia & Cachexia in CKD 7.3 Diagnostic Prioritization across Cardiorenal & Diabetic Nephropathy
8 Chapter 8: Domain 2 — Food & Nutrient Delivery: Protein & Energy
8.1 KDOQI 2020 Protein Targets: Non-Dialysis CKD (LPD vs. VLPD) 8.2 Protein Prescriptions for Hemodialysis and Peritoneal Dialysis 8.3 Energy Requirements, Carbohydrates & Plant-Dominant Diets (PLADO)
9 Chapter 9: Domain 2 — Electrolytes, Fluid, Acid–Base & Micronutrients
9.1 Potassium Management: Dietary Restriction, Leaching & K-Binders 9.2 Sodium & Fluid Prescriptions across Dialysis Modalities 9.3 Acid-Base Homeostasis & Bicarbonate Replacement Therapy 9.4 Micronutrient, Trace Mineral & Vitamin Supplementation in ESRD
10 Chapter 10: Domain 2 — Medications & Specialized Nutrition Support
10.1 CKD-MBD Pharmacology: Phosphorus Binders, Vitamin D & Calcimimetics 10.2 Anemia Management: Iron Homeostasis, IV Iron Protocols & ESAs 10.3 Enteral, IDPN & Intraperitoneal Amino Acid Nutrition Support
11 Chapter 11: Domain 2 — Treatments Across the Continuum: Transplant & Comorbidities
11.1 Kidney Transplant I: Candidacy, Living Donors & the Early Post-Transplant Period 11.2 Kidney Transplant II: Long-Term Care, Immunosuppressant Side Effects & Graft Protection 11.3 Diabetes Management Across CKD Stages: Glycemic Targets, Medications & MNT 11.4 GI & Cardiovascular Comorbidities: Gastroparesis, Constipation, Liver Disease, Lipids & Blood Pressure
12 Chapter 12: Domain 2 — Monitoring & Evaluation: Labs, Fluid & Nutrition Trends
12.1 Renal Laboratory Surveillance: Frequency, Target Ranges & Trending 12.2 Monitoring Fluid Balance, Blood Pressure & Cardiovascular Risk 12.3 Longitudinal Assessment of Nutritional Status & Weight Trajectories
13 Chapter 13: Domain 2 — Monitoring Dialysis Adequacy & Kinetics
13.1 Hemodialysis Adequacy: Urea Kinetic Modeling, spKt/V & URR 13.2 Peritoneal Dialysis Adequacy & Peritoneal Equilibration Test (PET) 13.3 Normalized Protein Catabolic Rate (nPCR / nPNA) Interpretation 13.4 Troubleshooting Inadequate Dialysis vs. Dietary Non-Adherence
14 Chapter 14: Domain 2 — Care Coordination, Communication & Education
14.1 Interdisciplinary Team Care, Patient Education & Counseling Ethics 14.2 Individualized & Group Education: Medicare MNT and KDE Benefits, Caregivers & Curricula 14.3 Interfacility Coordination of Care: Hospital Handoffs, Transfers, Transplant Centers & Modality Changes 14.4 Psychosocial Support & Resources: Food Assistance, Financial Programs, Rehabilitation & Peer Support
15 Chapter 15: Domain 3 — Regulations & Quality Management
15.1 CMS Conditions for Coverage: IDT, Dietitian Qualifications, Assessment & Plan-of-Care Timelines 15.2 QAPI Programs, PDSA Cycles & the ESRD Quality Incentive Program 15.3 Medicare ESRD Payment, ESRD Networks, EQRS & the Survey Measures Assessment Tool
16 Chapter 16: Domain 3 — Evidence-Based Practice: Guidelines, Research & Protocols
16.1 The KDOQI 2020 Nutrition in CKD Guideline (NKF–Academy EAL): Grades & Key Statements 16.2 KDIGO & Companion Guidelines: CKD 2024, CKD-MBD, Anemia 2026, Diabetes, BP, Lipids & AKI 16.3 Appraising Current Research: Study Designs, Bias, Statistics & Landmark Renal Trials 16.4 Clinical Protocols & Algorithms: Dietitian-Managed MBD, Anemia, Potassium & Nutrition-Support Pathways
4.2 Medical & Medication History: Drug–Nutrient Interactions and Supplements
Key Takeaways Explain This Topic AI
CMS requires the dialysis comprehensive assessment to include comorbid conditions, a laboratory profile, immunization history and medication history (42 CFR 494.80(a)(1) and (a)(3)).
Fluoroquinolone antibiotics should be taken at least 2 hours before or 6 hours after phosphate binders and other calcium-, iron- or zinc-containing products because they form chelates.
Grapefruit, pomelo and Seville orange inhibit intestinal CYP3A4 and can sharply raise tacrolimus and cyclosporine levels; St. John's wort lowers them.
Patiromer should be separated from other oral drugs by 3 hours; sodium zirconium cyclosilicate by 2 hours from drugs with pH-dependent absorption.
Herbal products such as noni juice, alfalfa and nettle add potassium; star fruit is neurotoxic in advanced CKD; and creatine supplements raise serum creatinine without changing true GFR.
Last updated: September 2026
Why medical and medication history is its own exam topic
The October 2023 CSR outline lists medical and medications history as a separate assessment area. Two task statements sit behind it: evaluate drug–drug and drug–nutrient interactions and evaluate the prescribed medication and dietary supplement regimen, timing and adherence . The CMS Conditions for Coverage (42 CFR 494.80) require the facility's comprehensive assessment to include the patient's current health status and co-morbid conditions (§494.80(a)(1)) and a laboratory profile, immunization history and medication history (§494.80(a)(3)). KDOQI 2020 (statement 1.6.1) also tells dietitians to look beyond intake to medication use, knowledge, beliefs, food access, depression and cognition when planning nutrition interventions.
A typical maintenance dialysis patient takes a dozen or more prescription drugs, and phosphate binders make up a large share of the pill count. Many of these drugs change appetite, electrolytes, glucose or micronutrient status. Others fail if they are taken at the wrong time relative to food or to other drugs.
What to capture in the medical history
Kidney history: cause of kidney disease (diabetes, hypertension, glomerulonephritis, polycystic kidney disease, obstruction), CKD stage or dialysis vintage and modality, residual urine output, prior transplants and access history.
Comorbidities: diabetes and its complications (gastroparesis, retinopathy, neuropathy), heart failure and coronary disease, liver disease, GI disorders, cancer, depression and cognitive impairment.
Events and procedures: recent hospitalizations, surgeries, amputations, infections, peritonitis episodes and wound status.
Surgical history with nutrition consequences: bariatric surgery (fat malabsorption raises enteric oxalate absorption and kidney-stone risk; micronutrient deficiencies), bowel resection, gastrectomy.
Dental and swallowing status, and vision and hand function , all of which affect the ability to prepare and eat food.
Medication reconciliation as a nutrition task
Medication reconciliation is also a quality measure: the PY 2028 ESRD Quality Incentive Program keeps a Medication Reconciliation (MedRec) reporting measure. The dietitian's part is to confirm what the patient actually takes, when, and with what. A "brown-bag" review, where the patient brings every bottle, box and supplement, often finds binders taken at bedtime, duplicated vitamins or an unreported herbal tea.
High-yield drug–nutrient interactions in renal practice
Drug or class Interaction or nutrition effect What the dietitian does
Phosphate binders (calcium acetate or carbonate, sevelamer, lanthanum, sucroferric oxyhydroxide, ferric citrate) Work only with food; can bind other drugs in the gut Pair with meals and snacks; check separation from interacting drugs with the pharmacist
Fluoroquinolones (e.g., ciprofloxacin), tetracyclines Chelated by calcium, iron, zinc, magnesium, aluminum and polymeric binders Ciprofloxacin labeling: take it at least 2 hours before or 6 hours after these products
Levothyroxine Absorption reduced by calcium, iron, sevelamer and lanthanum Separate by several hours; watch TSH trends
Oral iron Absorption reduced by calcium, binders, proton pump inhibitors, tea and coffee Take apart from binders; ferric citrate is itself an iron source
Patiromer Binds many oral drugs Separate other oral drugs by at least 3 hours
Sodium zirconium cyclosilicate Raises gastric pH transiently Separate by 2 hours from drugs with pH-dependent absorption; adds about 400 mg sodium per 5 g
Sodium polystyrene sulfonate Binds other drugs; bowel injury risk Labeling advises separating other oral drugs by at least 3 hours (6 hours with gastroparesis)
ACE inhibitors, ARBs, mineralocorticoid antagonists, trimethoprim, calcineurin inhibitors, NSAIDs Raise serum potassium Rule out drug causes before tightening potassium restriction
Loop and thiazide diuretics Potassium and magnesium losses Monitor; potassium restriction may not be needed
SGLT2 inhibitors Volume depletion; euglycemic ketoacidosis with prolonged fasting or very-low-carbohydrate diets Avoid prolonged fasting plans; teach sick-day rules with the prescriber
Metformin Lowers vitamin B12 over time; FDA labeling contraindicates use below eGFR 30 Check B12; confirm eGFR-based dosing
Proton pump inhibitors Hypomagnesemia; reduced B12 and non-heme iron absorption Monitor magnesium, B12 and iron
Tacrolimus, cyclosporine Grapefruit, pomelo and Seville orange raise blood levels; St. John's wort lowers them; hyperkalemia, hypomagnesemia, hyperglycemia Counsel on these foods and herbs; monitor potassium, magnesium and glucose
Corticosteroids Hyperglycemia, increased appetite, muscle catabolism, bone loss Carbohydrate and weight counseling; calcium and vitamin D review
Warfarin Effect changes with vitamin K intake Keep vitamin K intake consistent; KDOQI 2020 advises no vitamin K supplements for patients on warfarin-type drugs
Opioids, calcium binders, oral iron Constipation, which reduces colonic potassium excretion Fiber, fluid within limits, bowel regimen
Supplements and herbal products
Many patients do not think of teas, powders or "natural" remedies as medications, so ask directly and without judgment. High-risk products for people with kidney disease include:
Potassium sources: potassium-chloride salt substitutes, noni juice, alfalfa, dandelion, nettle and horsetail preparations.
Star fruit (carambola): contains a neurotoxin that accumulates in advanced CKD and can cause hiccups, confusion or seizures. Patients on dialysis should avoid it.
Aristolochic acid: causes a progressive nephropathy. It has been found in imported herbal products despite FDA warnings.
Licorice root (glycyrrhizin): mineralocorticoid-like effects cause sodium retention, hypertension and hypokalemia.
Creatine supplements (and very large cooked-meat meals): raise serum creatinine and falsely lower creatinine-based eGFR.
High-dose vitamin C: increases oxalate generation. Vitamin A-containing multivitamins add to retinol that already accumulates in CKD.
Magnesium- or aluminum-containing antacids and laxatives, and sodium phosphate enemas: cause hypermagnesemia, aluminum loading or acute phosphate loads.
High-dose biotin (often in hair and nail products): interferes with some immunoassays, including certain thyroid and troponin tests, so tell the lab.
Putting the history to work
Record medications and supplements in the client-history part of your assessment. Look for timing errors (binders at bedtime) and interacting pairs (ciprofloxacin swallowed with calcium acetate). Check whether a drug explains a lab abnormality before you change the diet. Send prescribing questions to the nephrologist or pharmacist. The dietitian changes food timing, counseling and supplement choices; the prescriber changes the drug.